Another review by Brown et al. highlighted that there is compelling data on the benefits of these drugs for a range of other clinical indications even without type 2 diabetes, including for GLP-1 RA in patients with obesity and overweight with weight-related comorbidities. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.